Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07025512 · ClinicalTrials.gov registry record · Phase 2
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
A Phase 2 study of Anemia and Metastatic Castration-Resistant Prostate Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07025512 is a Phase 2 study of Anemia and Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07025512, a Phase 2 study of Anemia and Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to examine the clinical and biological effects of 177Lu-PSMA-617 in mCRPC patients with cytopenia\[s\].
Conditions Studied
Interventions
- DRUG 177Lu-PSMA-617
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07025512
The ClinicalTrials.gov registry entry for NCT07025512 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (91% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which 177Lu-PSMA-617 is the first listed.
NCT07025512 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07025512 about?
NCT07025512 is a clinical study titled "177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia". The purpose of the study is to examine the clinical and biological effects of 177Lu-PSMA-617 in mCRPC patients with cytopenia\[s\].
What is the current status of trial NCT07025512?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-12-03. Estimated completion is 2029-06-30.
What conditions does trial NCT07025512 study?
This clinical trial studies the following conditions: Anemia, Metastatic Castration-Resistant Prostate Cancer, Thrombocytopenia, Cytopenia.
What interventions are being tested in trial NCT07025512?
The interventions under investigation include: 177Lu-PSMA-617 (DRUG).
Who is sponsoring clinical trial NCT07025512?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07025512 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.